CL2020001089A1 - Compuestos inhibidores de tirosina cinasa de bruton (btk). - Google Patents

Compuestos inhibidores de tirosina cinasa de bruton (btk).

Info

Publication number
CL2020001089A1
CL2020001089A1 CL2020001089A CL2020001089A CL2020001089A1 CL 2020001089 A1 CL2020001089 A1 CL 2020001089A1 CL 2020001089 A CL2020001089 A CL 2020001089A CL 2020001089 A CL2020001089 A CL 2020001089A CL 2020001089 A1 CL2020001089 A1 CL 2020001089A1
Authority
CL
Chile
Prior art keywords
btk
bruton
tyrosine kinase
inhibitor compounds
diseases
Prior art date
Application number
CL2020001089A
Other languages
English (en)
Inventor
Kenneth James Henry Jr
Albert Khilevich
Steven Lee Kuklish
Katherine Marie Partridge
Steven James Quimby
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2020001089A1 publication Critical patent/CL2020001089A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS INHIBIDORES DE BTK, SALES FARMACÉUTICAMENTE ACEPTABLES, COMPOSICIONES FARMACÉUTICAS DE LOS MISMOS, Y MÉTODOS PARA USAR ESTOS COMPUESTOS, SALES, O COMPOSICIONES PARA TRATAR ENFERMEDADES AUTOINMUNES TALES COMO ARTRITIS REUMATOIDE.
CL2020001089A 2017-11-06 2020-04-23 Compuestos inhibidores de tirosina cinasa de bruton (btk). CL2020001089A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762581967P 2017-11-06 2017-11-06

Publications (1)

Publication Number Publication Date
CL2020001089A1 true CL2020001089A1 (es) 2020-10-23

Family

ID=64277913

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001089A CL2020001089A1 (es) 2017-11-06 2020-04-23 Compuestos inhibidores de tirosina cinasa de bruton (btk).

Country Status (34)

Country Link
US (1) US11542249B2 (es)
EP (1) EP3707133B1 (es)
JP (1) JP6920553B2 (es)
KR (1) KR102410202B1 (es)
CN (1) CN111278818B (es)
AR (1) AR113796A1 (es)
AU (1) AU2018360478B2 (es)
BR (1) BR112020006749A2 (es)
CA (1) CA3080123C (es)
CL (1) CL2020001089A1 (es)
CR (1) CR20200183A (es)
CY (1) CY1124994T1 (es)
DK (1) DK3707133T3 (es)
DO (1) DOP2020000103A (es)
EA (1) EA039398B1 (es)
EC (1) ECSP20024395A (es)
ES (1) ES2904843T3 (es)
HR (1) HRP20220178T1 (es)
HU (1) HUE057987T2 (es)
IL (1) IL273778B (es)
JO (1) JOP20200104A1 (es)
LT (1) LT3707133T (es)
MA (1) MA50561B1 (es)
MD (1) MD3707133T2 (es)
MX (1) MX2020004435A (es)
PE (1) PE20201168A1 (es)
PL (1) PL3707133T3 (es)
PT (1) PT3707133T (es)
RS (1) RS62805B1 (es)
SG (1) SG11202003178PA (es)
SI (1) SI3707133T1 (es)
TW (1) TWI694995B (es)
UA (1) UA126079C2 (es)
WO (1) WO2019089512A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220175772A1 (en) * 2019-05-23 2022-06-09 Novartis Ag Methods of treating sjogren's syndrome using a bruton's tyrosine kinase inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2426109B1 (en) * 2007-10-23 2013-12-18 F. Hoffmann-La Roche AG Novel kinase inhibitors
SG185462A1 (en) * 2010-05-07 2012-12-28 Gilead Connecticut Inc Pyridone and aza-pyridone compounds and methods of use
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
CA2833771C (en) 2011-06-10 2021-08-03 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
WO2014093230A2 (en) * 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
GB2516303A (en) * 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors

Also Published As

Publication number Publication date
PE20201168A1 (es) 2020-10-28
MA50561B1 (fr) 2022-03-31
AU2018360478B2 (en) 2020-09-17
DK3707133T3 (da) 2022-01-03
JOP20200104A1 (ar) 2022-10-30
HRP20220178T1 (hr) 2022-04-29
RS62805B1 (sr) 2022-02-28
US20200290997A1 (en) 2020-09-17
PT3707133T (pt) 2022-01-27
TW201930293A (zh) 2019-08-01
US11542249B2 (en) 2023-01-03
SI3707133T1 (sl) 2022-02-28
CN111278818B (zh) 2023-03-28
EA039398B1 (ru) 2022-01-24
NZ764452A (en) 2023-09-29
AR113796A1 (es) 2020-06-10
LT3707133T (lt) 2022-01-25
IL273778B (en) 2022-06-01
EA202090843A1 (ru) 2020-07-24
DOP2020000103A (es) 2020-09-15
AU2018360478A1 (en) 2020-04-23
BR112020006749A2 (pt) 2020-10-06
ES2904843T3 (es) 2022-04-06
KR20200060480A (ko) 2020-05-29
PL3707133T3 (pl) 2022-04-04
MA50561A (fr) 2020-09-16
EP3707133A1 (en) 2020-09-16
ECSP20024395A (es) 2020-06-30
JP6920553B2 (ja) 2021-08-18
JP2021501749A (ja) 2021-01-21
CA3080123A1 (en) 2019-05-09
CN111278818A (zh) 2020-06-12
CY1124994T1 (el) 2023-01-05
SG11202003178PA (en) 2020-05-28
CA3080123C (en) 2021-11-09
HUE057987T2 (hu) 2022-06-28
TWI694995B (zh) 2020-06-01
IL273778A (en) 2020-05-31
EP3707133B1 (en) 2021-12-15
UA126079C2 (uk) 2022-08-10
CR20200183A (es) 2020-05-30
WO2019089512A1 (en) 2019-05-09
KR102410202B1 (ko) 2022-06-22
MX2020004435A (es) 2020-08-06
MD3707133T2 (ro) 2022-07-31

Similar Documents

Publication Publication Date Title
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CR20190301A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
UY36371A (es) Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
EA201792214A1 (ru) Соединения замещенного хиназолина
EA201792116A1 (ru) Ингибитор янус-киназы
PE20151501A1 (es) Inhibidores de prmt5 y sus usos
CL2018001996A1 (es) Composiciones y métodos para modular la expresión del factor b del complemento (divisional de solicitud 2764-16)
UY31384A1 (es) Novedosos compuestos heterociclicos para la inhibicion de la proteina quinasa b
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CO2019012571A2 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
NI201700055A (es) 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CL2019002240A1 (es) Dendrímeros terapéuticos.
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
AR096543A1 (es) INHIBIDORES DE QUINASA PI3 d Y g SELECTIVOS DUALES
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
EA201790276A1 (ru) Новые имидазопиридазиновые соединения и их применение
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
ECSP19019613A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
BR112017008312A2 (pt) novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms)